TPST Stock Performance, Insider Transaction and News

TPST - Tempest Therapeutics, Inc.

Market Cap	11.12M	P/E	-	EPS this Y	26.20%	Ern Qtrly Grth	-
Income	-29.49M	Forward P/E	-0.44	EPS next Y	-8.50%	50D Avg Chg	-26.00%
Sales	-	PEG	-	EPS past 5Y	-	200D Avg Chg	-43.00%
Dividend	N/A	Price/Book	0.92	EPS next 5Y	-	52W High Chg	-77.00%
Recommedations	1.50	Quick Ratio	4.17	Shares Outstanding	22.22M	52W Low Chg	7.00%
Insider Own	0.06%	ROA	-37.31%	Shares Float	17.77M	Beta	-2.83
Inst Own	29.04%	ROE	-131.42%	Shares Shorted/Prior	1.13M/766.84K	Price	0.96
Gross Margin	-	Profit Margin	-	Avg. Volume	73,264	Target Price	18.60
Oper. Margin	-	Earnings Date	May 8	Volume	31,367	Change	4.35%

Healthcare | Biotechnology | United States

About Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Tempest Therapeutics, Inc. News

04/26/24	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/09/24	Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
04/04/24	Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
03/19/24	Tempest Reports Year End 2023 Financial Results and Provides Business Update
03/12/24	Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
03/05/24	Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
02/26/24	Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
11/20/23	Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
11/08/23	Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
10/12/23	Tempest Therapeutics, Inc.'s (NASDAQ:TPST) largest shareholders are private equity firms who were rewarded as market cap surged US$127m last week
10/11/23	Tempest Adopts Limited Duration Stockholder Rights Plan
10/11/23	Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
10/10/23	Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
09/19/23	Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
09/05/23	Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08/10/23	Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
07/19/23	Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
05/31/23	Tempest to Present at the Jefferies Global Healthcare Conference
05/25/23	Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
05/19/23	Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TPST Chatroom

IlLaskan Posted - 7 minutes ago

$TPST

Johnquest123 Posted - 40 minutes ago

$TPST why are people idiots putting in outdated info here ?

AngelW86 Posted - 23 hours ago

$TPST 1. “Our presentation at the ASCO Annual Meeting 2024 marks a pivotal moment in our journey to transform cancer treatment.”: This suggests that the company has been given an opportunity to present at a significant event in the field of oncology (cancer treatment). 2. “The encouraging data from our TPST-1120 study not only validate our scientific approach but also strengthen our resolve to deliver innovative treatments that can significantly improve patient outcomes.”: This part highlights that the data from their study, specifically regarding TPST-1120, is positive and supports the company’s scientific approach to cancer treatment. It suggests that the results are promising and align with the company’s goals of developing innovative treatments to help patients. Overall, the statement indicates a positive development for the company, as it suggests progress in their efforts to advance cancer treatment and potentially bring new, effective therapies to market.

Bigdayswing Posted - 1 day ago

$TPST this says it all.. Loose lips sink ships don't tell anyone... shhhhhh. https://www.globenewswire.com/news-release/2024/04/04/2857718/0/en/Tempest-Announces-Publication-of-Positive-Data-from-Phase-1-Trial-of-TPST-1120-in-Patients-with-Advanced-Solid-Tumors-in-Journal-of-Cancer-Research-Communications.html

Bigdayswing Posted - 1 day ago

$TPST #asco2024 $tpst read the quote from the ceo. 💣 https://www.marketscreener.com/quote/stock/TEMPEST-THERAPEUTICS-INC-124221532/news/Tempest-Therapeutics-Announces-Groundbreaking-Advances-in-Liver-Cancer-Treatment-Showcasing-Excepti-45838238/

Bigdayswing Posted - 1 day ago

@josegodoy doesn't say anything about t $TPST

josegodoy Posted - 1 day ago

$TPST Roche (2 days old)…. “The drugmaker needs to terminate some programs to free up cash to invest in accelerating “a number of projects that have a high likelihood to succeed and have a huge patient impact,” Schinecker said.” https://www.fiercebiotech.com/biotech/roches-pipeline-rethink-hits-20-new-molecules-cancer-candidates-join-discard-pile

PRG2022 Posted - 1 day ago

$TPST Hmmmmm. So ASCO is going to feature TPST talking about a Phase 1 result from BMS. Nothing from Roche. Feels like we are going backwards and Roche is out.

Harleybug Posted - 1 day ago

$TPST this stock will be in the 3-5 price range for along time my quess is they will dilute to fund 1120 shorting will be the only way to make any money here , everyone telling you to hold is full of shit!

Thestokinator Posted - 1 day ago

$TPST hmmmmmmmm! 😂 got burned at sls!

MBA_Certified Posted - 1 day ago

$TPST Hmmmm

Stock_Titan Posted - 1 day ago

$TPST Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/TPST/tempest-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-o4i7d5ihfan7.html

brotherearl Posted - 1 day ago

$TPST have a great weekend to ALL, TPST stock holders.

Thestokinator Posted - 1 day ago

$TPST stupid kid!

chump2234 Posted - 2 days ago

$TPST Was all over djt at $22.00.

brotherearl Posted - 2 days ago

$TPST yup, just waiting on my funds to clear

fuegie Posted - 2 days ago

$TPST was rejected again at the 200ma. It needs to hold 3.40, though, or else it could drop again.

5xStarTrader Posted - 2 days ago

$TPST Oh look! Those counterfeit shares that were sold short yesterday to "bloat the float" were then immediately made available to borrow for shorting the stock! Makes you wonder if the low availability of shares to borrow led the naked shorting volume.... https://www.iborrowdesk.com/report/TPST

5xStarTrader Posted - 2 days ago

$TPST You would think that by shorting 66% of all stock purchases yesterday that the MMs (who I believe are responsible for 90% of short sales) are trying to suppress the stock price.... http://shortvolumes.com/?t=tpst

Thestokinator Posted - 2 days ago

$TPST good stay down!

Papermoon347 Posted - 2 days ago

$TPST Hopefully we have another close like yesterday.

NewHighEveryDay Posted - 2 days ago

$TPST premature ejection now lol 😂

Bigdayswing Posted - 2 days ago

$TPST good day for tpst

NewHighEveryDay Posted - 2 days ago

$TPST

wagonelli Posted - 2 days ago

$TPST flippers raise your ask, she's trying to get up and go back where she belongs

vuh Posted - 2 days ago

$TPST need some volume and this will run.

Elvis50 Posted - 2 days ago

$TPST I'll say it again, a lot of tinder on the ground. Just one spark......

Rasco Posted - 2 days ago

@Ellie_C $ADXN, $GRTS, $JAGX, $TPST. My investments - all go-for-broke names. Am I sane?

Harleybug Posted - 2 days ago

$TPST weak !

zambono Posted - 2 days ago

@PRG2022 low float and big insider / institutional holdings. That is the way $TPST

Analyst Ratings

HC Wainwright & Co.	Buy	Mar 20, 24
Scotiabank	Sector Outperform	Mar 14, 24
Scotiabank	Sector Outperform	Mar 13, 24
HC Wainwright & Co.	Buy	Mar 12, 24
Jefferies	Buy	Feb 8, 24
HC Wainwright & Co.	Buy	Oct 11, 23
HC Wainwright & Co.	Buy	Aug 11, 23
HC Wainwright & Co.	Buy	Jun 5, 23
HC Wainwright & Co.	Buy	May 30, 23

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Woiwode Thomas	Director Director	Apr 29	Buy	2.36	2,118,644	5,000,000	2,118,644	05/03/22
Dubensky Thomas W.	President President	Jan 07	Buy	4.78	2,000	9,560	113,343	01/11/22
Whiting Samuel	Chief Medical Office.. Chief Medical Officer	Jan 06	Buy	4.8048	1,700	8,168	1,901	01/10/22